Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event

  • Scinai will exhibit at the upcoming CPHI Barcelona event, showcasing its CDMO services
  • The company expanded into the CDMO business earlier this year, operating under the banner Scinai Bioservices
  • Scinai’s boutique end-to-end CDMO business division serves pharmaceutical, biotech, and alternative protein food tech companies with pilot and clinical process development and cGMP manufacturing
  • Scinai intends to serve small biotech companies who require CDMO services with superior value compared to large, multinational CDMO companies
  • Scinai will also exhibit at the upcoming BIO-Europe conference in Munich

Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, will be showcasing its Contract Development and Manufacturing Organization (“CDMO”) services at CPHI Barcelona, a premier three-day event that brings together pharmaceutical professionals, industry leaders, and businesses to advance human health. The event is scheduled for October 24 to 26, 2023, at Fira Barcelona Gran Via, Spain (https://ibn.fm/veEp4).

The company has been allocated Booth 81HA11, where potential partners and clients of the company’s CDMO service will get to meet several members of Scinai’s executive leadership team. Registered attendees may also request one-on-one meetings through the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.